Oscar Health's CEO bought $12 million of stock near the lows, an eight-figure insider buy worth paying attention to. Shares are now at 5.5-year highs and close to threatening the all-time high set at the IPO price. x.com 

Oscar Health is a must-buy because its CEO is buying while the market misprices a short-term headwind, and CEOs can see one to two quarters ahead. x.com 

Oscar Health looks too extended after its big move and should pull back around earnings in the next few days; it is not a tech stock with a niche product capable of parabolic moves. x.com 

Oscar Health's run has just started. The market liked the CEO buying stock, the reaffirmed 2026 guidance and last quarter's first-ever operating profit. x.com  x.com 

Oscar Health has the most room to run among health insurers, which are rallying after the administration announced increased Medicaid budgets. CEO Mark Bertolini bought about $12 million of shares at the lows, the first insider purchase this year, and Oscar's market cap is just $3.74B. The chart confirms it: a broken daily descending trendline, surging money flow and a volume spike. Resistance sits at $14.15-$15, and a close above $15 brings the 200-day moving average into play. x.com 

Oscar Health's raised 2026 guidance changes nothing fundamentally, so its 18%+ premarket jump is unlikely to hold. Operating earnings guidance rose to $500-700M from $250-450M, but Oscar had already booked $704M in Q1 alone, more than the new top end, with Q3 and Q4 seasonally bringing losses. 2027 could be challenging as management targets a 5% margin, and the stock looks fairly valued around $34. x.com  x.com 

Oscar Health's record Q1 and CEO insider buying set it up to break out of a 24-month accumulation base. The tech-driven insurer, spanning ACA, Medicare and small-group markets, grew revenue 53% and earned $2.07 a share versus $1.11 expected, and its CEO bought 1 million shares in April. A clean close above $24, where it has been rejected repeatedly, is needed before it heads higher. x.com 

Oscar Health has already priced in the CMS crackdown while it keeps disrupting medical insurance, with 90% average annual sales growth over the past five years. The stock is not far from testing new highs since its IPO, and the price target is 42+. x.com 

Hyped growth stocks can be poor investments even when their businesses grow, because valuations already assume they will become exceptional. Retail buyers often arrive after the promise is widely recognized, before tougher competition separates lasting winners from the rest. Eight of the nine previously warned-about stocks have fallen, though Oscar Health has gained. x.com 

Oscar Health's drop below $30 makes little sense after it crushed Q2, swung to a profit and raised full-year operating earnings guidance. Revenue was $4.90B versus $4.75B expected and EPS $1.10 versus $0.39, with FY26 revenue guided to $18.9B versus $18.6B estimated. The market needs time to digest the result, and the stock should recover soon; it remains a long-term hold. x.com  x.com  x.com